Market Introduction
Asia Pacific includes countries such as China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. This region accounted for being fastest-growing region of the global protein binding assay market in 2019 owing to substantial number of CROs operating in the space; growing pressure to reduce drug discovery and development costs; growing healthcare expenditure; increase in developments in the pharmaceutical and biotechnological industries in India and China; expanding research base across India, China, and Japan; and increasing pharmaceutical R&D expenditure. In the Asia Pacific region, China is the largest market for protein binding assay. The growth of the market is primarily attributed to several new discoveries driven by research & development and rising number of clinical trials in the country. The growth of the market is attributed to the increasing R&D activities, rising investments in the healthcare sector in developing countries, and increasing collaborations between regulatory outsourcing and drug developers. As per the Government of China in January 2018, China's 13th five-year plan stipulates that biotechnology sector is expected to exceed around 4% of gross domestic product by 2020. Also, China has more than 100 life science parks and approx. USD 100 billion has already been invested by Chinese government to promote biotechnology. In December 2018, PAREXEL, a leading innovator in global biopharmaceutical services, announced a new collaboration with Eli Lilly and Company to launch a clinical research learning and development program in China. The program will provide high-value training opportunities for Chinese clinical trial sites and investigators, enhance local clinical trials, and drive innovation in China's biopharmaceutical industry. To encourage innovation in drug development, the Chinese government has recently launched a series of new policies for clinical research, resulting in a sharp increase in the number of clinical trials in China. According to China's clinical trial registration platform, 1,258 drug clinical trials were first registered and published in China in 2017, an increase of 62.66% compared to 2016. A recent report indicates that the total number of class 1.1 chemical drugs and class 1 biologic drugs approved for clinical trials from January to October 2017 was three times that of 2014. However, the number of GCP-qualified clinical trial sites did not increase significantly between 2014 and 2016. In 2017, China implemented sweeping reforms to its regulatory system, closely aligning the rules governing the world's second-largest drug market with the US and Europe. The result was a sharp rise in applications by Chinese biotech companies to register innovative therapies in the US. IND filings jumped from 11 in 2016 to 20 in 2017 and almost doubled again with an additional 38 applications in 2018 and the first quarter of this year. Chinese policy changes also prompted Western firms to tap China's much larger patient pool to simultaneously access high-quality clinical data to support US registration and, around the same time, to gain rapid registration in China. The increasing adoption of protein binding assays in drug discovery & development offering lucrative opportunities for the protein binding assay market
According to Worldometer, from its epicenter in China, SARS-CoV-2 has spread to infect ~58,231,688 people in Asia, as of July 29, 2021. Following the terrible loss of lives, economies in Asia Pacific have collapsed during the pandemic. The pandemic has emphasized health data exchange and interoperability under a microscope. The supply chain disruptions, along with the tremendous demand for efficient treatments against COVID-19, have put the healthcare research industry in a crucial situation in region. Socioeconomics in countries such as India, China, Japan, and South Korea were severely affected, resulting in rise in inflation, decrease in GDP, and surge in unemployment. Countries such as China, Japan, Singapore, and South Korea show large interest in clinical trials. High costs in western countries drives the flow of medical affairs outsourcing to Asia Pacific. Moreover, pharmaceutical companies are becoming aware of new and changing regulatory environments for drugs, devices, and in vitro diagnostics to expand sales to the Asian market. Asian countries have been at a forefront of updating GMP standards and medical device regulatory systems and introducing drug price controls. Third-party guidance and advice are required as part of any acquisition or any improvement of current standards. Increasingly, third-party outsourcing service providers are playing a greater role in supporting the protein binding assay market progress in Asia Pacific.
Market Overview and Dynamics
The protein binding assay market in APAC is expected to grow from US$ 73.34 million in 2021 to US$ 153.72 million by 2028; it is estimated to grow at a CAGR of 11.2% from 2021 to 2028. Rising pressure to reduce drug discovery and development costs; the cost of developing new drugs remains high at an inflation-busting rate, and returns and profits on investments are declining, placing pressure on the entire innovative medicine system. Many research-based pharmaceutical and biopharmaceutical companies are reevaluating old R&D policies and focusing their efforts on improving efficiency, increasing output, and satisfying unmet patient requirements due to current economic and political pressures to reduce the healthcare cost. The changing focus on drug discovery and development, and the rising use of new technologies for identifying and screening drug candidates create new opportunities to target various chronic, degenerative, and life-threatening diseases that were previously untargeted. The process of discovering and developing a drug is costly, as it requires investments in funding, human resources, and technologies. Before launching a new drug in the market, strict adherence to regulations on testing and manufacturing standards is required. Furthermore, if a drug candidate fails during the development stage, the entire investment gets wasted. Protein binding studies aid in the optimization of drug discovery expenses by assessing binding and absorption capabilities in preclinical phases, resulting in lower drug attrition in the late stages of development. Thus, rising pressure to reduce drug discovery and development costs driving the market growth.
Key Market Segments
Based on technology is segmented into ultracentrifugation ultrafiltration, equilibrium dialysis, surface plasmon and others. In 2020, the equilibrium dialysis segment is likely to hold the largest share of the market, by technology. Based on the end user was segmented into contract research organization, pharmaceutical & biotechnology companies, and research & diagnostic laboratories. In 2020, the pharmaceutical & biotechnology companies segment is likely to hold the largest share of the market, by end user.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the protein binding assay market in APAC are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Biotium, Inc, Eurofins Scientific, General Electric Company, MERCK KGaA, MicroConstants, Inc, Pharmaron Beijing Co., Ltd, Sartorius AG, SOVICELL GMBH, and THERMO FISHER SCIENTIFIC INC. among others.
Reasons to buy report
APAC PROTEIN BINDING ASSAY MARKET SEGMENTATION
By Technology
By End User
By Country
Company Profiles